Shattuck Labs, Inc. (STTK)

NASDAQ: STTK · IEX Real-Time Price · USD
8.86
-0.12 (-1.34%)
Mar 28, 2024, 1:19 PM EDT - Market open

Company Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States.

The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs, Inc.
Shattuck Labs logo
Country United States
Founded 2016
IPO Date Oct 9, 2020
Industry Biotechnology
Sector Healthcare
Employees 75
CEO Dr. Taylor H. Schreiber M.D., Ph.D.

Contact Details

Address:
500 W. 5th Street
Austin, Texas 78701
United States
Phone 512-900-4690
Website shattucklabs.com

Stock Details

Ticker Symbol STTK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001680367
CUSIP Number 82024L103
ISIN Number US82024L1035
Employer ID 81-2575858
SIC Code 2834

Key Executives

Name Position
Dr. Taylor H. Schreiber M.D., Ph.D. Co-Founder, Chief Executive Officer and Director
Dr. Abhinav A. Shukla Ph.D. Chief Technical Officer
Dr. Arundathy Nirmalini Pandite M.B.A., M.D. Chief Medical Officer
Andrew R. Neill M.B.A. Chief Financial Officer
Conor Richardson CPA Vice President of Investor Relations
Dr. Stephen Stout J.D., Ph.D. General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
Casi DeYoung Chief Business Officer
Dr. Thomas Lampkin Pharm.D. Senior Vice President of Regulatory Affairs
George Fromm Ph.D. Chief Scientific Officer of ARC Platform
Suresh de Silva Ph.D. Chief Scientific Officer of GADLEN Platform

Latest SEC Filings

Date Type Title
Mar 6, 2024 144 Filing
Mar 4, 2024 8-K Current Report
Feb 29, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 29, 2024 10-K Annual Report
Feb 29, 2024 8-K Current Report
Feb 13, 2024 8-K Current Report
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 2, 2024 424B3 Prospectus
Jan 31, 2024 EFFECT Notice of Effectiveness
Jan 30, 2024 UPLOAD Filing